Home LiteratureArticle Details
PMID: 1679332 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't

Characterization of pancreatic T lymphocytes associated with beta cell destruction in the non-obese diabetic (NOD) mouse.

Journal of autoimmunity ·Vol. 4 ·No. 2 ·1991-04-00 ·Pages 263-76

Kay TW, Campbell IL, Harrison LC

Abstract

Pancreatic beta cell destruction in the non-obese diabetic (NOD) mouse is mediated by T lymphocytes and macrophages and accelerated by cyclophosphamide. We purified pancreatic T lymphocytes from the NOD mouse for comparative phenotypic and functional analysis with T lymphocytes from spleen, peripheral blood and regional lymph nodes. Pancreatic T lymphocytes from NOD-Wehi mice, which have an incidence of spontaneous diabetes of less than 5%, had a CD4:CD8 ratio of 1.25 +/- 0.23 compared with 2.44 +/- 0.31 for peripheral blood lymphocytes. After cyclophosphamide, the CD4:CD8 ratio of pancreatic lymphocytes increased to 2.30 +/- 0.24 at day 7. T lymphocytes bearing IL-2 receptors increased two- to three-fold in number and their secretion of GM-CSF/IL-3 and IFN-gamma increased to a maximum on day 7. Pancreatic insulin content and mRNA levels declined sharply between days 10 and 12, at which time the majority of pancreatic T lymphocytes in hyperglycaemic mice were CD8+ (CD4:CD8 ratio 0.63 +/- 0.04 compared to 4.14 +/- 1.05 in peripheral blood). The pancreatic T lymphocyte CD4:CD8 ratio in prediabetic NOD-Lt mice, which have an incidence of spontaneous diabetes of about 60% at 150 days, was similar to that in untreated NOD-Wehi mice, but 25% of their pancreatic CD8 T lymphocytes were IL-2-receptor positive. Thus, significant changes in the phenotype of NOD pancreatic T lymphocytes following cyclophosphamide were not reflected in peripheral blood or spleen T lymphocytes. The earliest change after cyclophosphamide was an increase in activated, predominantly CD4+ T lymphocytes; with the development of beta cell destruction and hyperglycaemia, pancreatic T lymphocytes were, as in human IDDM, predominantly CD8+.

MeSH Terms
Animals CD4-Positive T-Lymphocytes/drug effects,pathology Cyclophosphamide/pharmacology Diabetes Mellitus, Experimental/genetics,immunology,pathology Hyperglycemia/immunology,pathology Insulin/analysis Islets of Langerhans/immunology,pathology Lymph Nodes/pathology Lymphokines/metabolism Mice Mice, Mutant Strains/immunology RNA, Messenger/analysis Receptors, Interleukin-2/analysis Spleen/pathology T-Lymphocyte Subsets/drug effects,immunology,pathology T-Lymphocytes, Cytotoxic/immunology,pathology
Chemicals
Insulin Lymphokines RNA, Messenger Receptors, Interleukin-2 Cyclophosphamide
Authors & Affiliations
3 authors, click to expand affiliations / ORCID
Kay T W
Walter and Eliza Hall Institute of Medical Research, Post Office Royal Melbourne Hospital, Parkville, Victoria, Australia.
Campbell I L
Harrison L C
Article Info
Journal
Journal of autoimmunity
Abbr.
J Autoimmun
ISSN
0896-8411
Published
1991-04-00
Pages
263-76
Language
English
Region
England
NLM ID
8812164
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com